One of the biggest trends in the fight against obesity has been the explosion in popularity of GLP-1 medications. Created to treat diabetes, patients who were prescribed the popular GLP-1 drugs Ozempic,…
Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. The telehealth company pulled its copycat semaglutide weight-loss pill over the weekend after threats of legal…
Hims & Hers Health (NASDAQ: HIMS) has had among the worst runs of any public company over the last year. And, there is little reason to think it will recover. The stock…
The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly (NYSE:LLY | LLY Price Prediction) and Novo Nordisk (NYSE:NVO) has intensified following their latest fourth-quarter earnings reports. Novo Nordisk initially dominated…
The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution. The fund’s concentrated bet on GLP-1 manufacturers makes this a call option…
Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. With promising new treatments in the pipeline, 24/7 Wall St. projects healthy upside through the end of the decade.
Joel South Live Updates Here’s Why Nike is Soaring Today12:41pm ETNike dropped from about $69 to a low of $56.99 on weak China sales, declining gross margins, and a cautious outlook over the last…
Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk‘s (NYSE:NVO | NVO Price Prediction) Wegovy weight-loss pill, the first of its kind. This once-daily tablet uses the same active ingredient —…
Rich Duprey Albemarle (NYSE: ALB | ALB Price Prediction) had an incredible year. Since bottoming out at around $50 in April, the lithium giant exploded to $145.38. This morning, it’s up another $4.15 and…
Shares of Novo Nordisk A/S (NYSE: NVO | NVO Price Prediction) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05. Sometimes we see a divergence in share…
If the headline yield today is not something you’re concerned with, and you pay more attention to how fast a yield can grow, then it’s worth buying dividend stocks you can forget…
In the past week or so, a biotech and an energy infrastructure giant saw some huge insider buying. These were not the only notable purchases though.
The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over…
The U.S. stock market has delivered impressive gains for over a decade, but warning signs of a potential downturn are mounting. Inflation remains sticky, interest rates hover at levels that could squeeze…
The Boom That Built Billion-Dollar Empires GLP-1 drugs have reshaped the pharmaceutical landscape, turning obesity and diabetes treatments into massive revenue streams for Novo Nordisk (NYSE:NVO | NVO Price Prediction) and Eli…
